Table 1 Clinicopathological features of subgroups

Age

64.43 (11.24)

68.37 (10.05)

64.89 (9.75)

71.84 (9.36)

< 0.0001

BMI

26.98 (5.29)

27.31 (5.79)

26.44 (5.80)

26.90 (5.73)

< 0.0001

Sex

0.567

 female

16 (23.9%)

33 (29.7%)

20 (21.3%)

22 (25.9%)

 male

51 (76.1%)

78 (70.3%)

74 (78.7%)

63 (74.1%)

Race

< 0.0001

 Asian

6 (9.0%)

6 (5.4%)

24 (25.5%)

6 (7.1%)

 Black

2 (3.0%)

7 (6.3%)

5 (5.3%)

3 (3.5%)

 White

56 (83.6%)

96 (86.5%)

57 (60.6%)

73 (85.9%)

 Not report

3 (4.5%)

2 (1.8%)

8 (8.5%)

3 (3.5%)

Lymphovascular

0.106

 Yes

26 (38.8%)

39 (35.1%)

26 (27.7%)

41 (48.2%)

 No

22 (32.8%)

41 (36.9%)

32 (34.0%)

20 (23.5%)

 Not report

19 (28.4%)

31 (27.9%)

36 (38.3%)

24 (28.2%)

Stage

< 0.0001

 Stage I

1 (1.5%)

0 (0%)

2 (2.1%)

0 (0%)

 Stage II

28 (41.8%)

24 (21.6%)

47 (50.0%)

15 (17.6%)

 Stage III

19 (28.4%)

46 (41.4%)

22 (23.4%)

33 (38.8%)

 Stage IV

18 (26.9%)

41 (36.9%)

22 (23.4%)

37 (43.5%)

 Not report

1 (1.5%)

0 (0%)

1 (1.1%)

0 (0%)

CMC subtype

< 0.0001

 Basal squamous

33 (49.3%)

75 (67.6%)

6 (6.4%)

8 (9.4%)

 Luminal

2 (3.0%)

3 (2.7%)

3 (3.2%)

17 (20.0%)

 Luminal infiltrated

4 (6.0%)

24 (21.6%)

2 (2.1%)

34 (40.0%)

 Luminal papillary

23 (34.3%)

7 (6.3%)

76 (80.9%)

23 (27.1%)

 Neuronal

5 (7.5%)

2 (1.8%)

7 (7.4%)

3 (3.5%)

 PD-L1

2.29 (1.11)

2.32 (1.09)

0.47 (0.25)

0.56 (0.25)

< 0.0001